Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Ovarian Epithelial 3Ovarian Neoplasms 2Endometrial Neoplasms 2Sarcoma, Endometrial Stromal 1Sarcoma 1Recurrent Uterine Corpus Sarcoma 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Thalidomide × Gynecologic × Clear all
NCT00004876 2013-08-26

Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00016224 2013-06-18

Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡